These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 10210515)

  • 21. Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential.
    Nair LA; Grant AO
    Cardiovasc Drugs Ther; 1997 Apr; 11(2):149-67. PubMed ID: 9140692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Class III antiarrhythmic agents: the next wave.
    Bauman JL
    Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia.
    Prystowsky EN
    Clin Cardiol; 1994 Sep; 17(9 Suppl 2):II7-10. PubMed ID: 7882612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias.
    Anderson JL
    Am J Cardiol; 1990 Jan; 65(4):36B-42B. PubMed ID: 2105050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety considerations in the pharmacological management of atrial fibrillation.
    Camm AJ
    Int J Cardiol; 2008 Jul; 127(3):299-306. PubMed ID: 18191470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of cardiac arrhythmias during pregnancy: safety considerations.
    Joglar JA; Page RL
    Drug Saf; 1999 Jan; 20(1):85-94. PubMed ID: 9935279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
    Chung MK; Schweikert RA; Wilkoff BL; Niebauer MJ; Pinski SL; Trohman RG; Kidwell GA; Jaeger FJ; Morant VA; Miller DP; Tchou PJ
    J Am Coll Cardiol; 1998 Jul; 32(1):169-76. PubMed ID: 9669266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
    Wolbrette DL
    Am J Cardiol; 2003 Mar; 91(6A):39D-44D. PubMed ID: 12670641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial.
    Anderson JL
    J Clin Pharmacol; 1990 Nov; 30(11):981-9. PubMed ID: 2122984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Pearls in Using Antiarrhythmic Drugs in the Outpatient Setting.
    Parker MH; Sanoski CA
    J Pharm Pract; 2016 Feb; 29(1):77-86. PubMed ID: 26602062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.
    McCauley M; Vallabhajosyula S; Darbar D
    Card Electrophysiol Clin; 2016 Jun; 8(2):481-93. PubMed ID: 27261836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.
    Das MK; Zipes DP
    J Cardiovasc Pharmacol; 2010 May; 55(5):438-49. PubMed ID: 20509177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What have clinical trials taught us about proarrhythmia?
    Skanes AC; Green MS
    Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review.
    Snider M; Kalbfleisch S; Carnes CA
    Clin Ther; 2009 Jun; 31(6):1209-18. PubMed ID: 19695388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy with and assessment of class III antiarrhythmic agents in different patient populations.
    Podrid PJ
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S44-58. PubMed ID: 1279309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.